Evidence map›Paper›PMID 33099429›Full record

ReviewHematology/oncology clinics of North America2020

Stem Cell Mobilization and Autologous Transplant for Immunoglobulin Light-Chain Amyloidosis.

Morie A Gertz, Stefan Schonland

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Hematology/oncology clinics of North America, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 11 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Morie A GertzDivision of Hematology, Mayo Clinic, 200 Southwest First Street, W10, Rochester, MN 55905, USA. Electronic address: gertz.morie@mayo.edu.
Stefan SchonlandDepartment of Internal Medicine V, Division of Hematology/Oncology, Amyloidosis Center, Heidelberg University Hospital, Im Neuenheimer Feld 450, Heidelberg 69120, Germany.
Mayo Clinic · USUniversity Hospital Heidelberg · DE

Funding

Project 4: Targeting Resistance to T-Cell Directed Therapy in Multiple MyelomaP50CA186781 · NCI · MAYO CLINIC ARIZONA · PI Rafael Fonseca · 2015 to 2026
$25.5M
NCI NIH HHS P50 CA186781
6 · The paper itself

Abstract

Stem cell transplantation was one of the first proven effective regimens for the management of immunoglobulin light-chain amyloidosis. Criteria for patient selection and the mobilization regimen become important features in ensuring a safe outcome. The technique of stem cell transplantation has evolved considerably in parallel with the development of new chemotherapeutic agents for the management of amyloidosis. Optimal outcomes require both the use of effective novel agent induction and appropriate application of high-dose chemotherapy with subsequent stem cell reconstitution.

Indexed as

Hematopoietic Stem Cell MobilizationHematopoietic Stem Cell TransplantationHumansImmunoglobulin Light-chain AmyloidosisTransplantation, AutologousHigh-dose chemotherapyMelphalanMobilizationTransplantation

Identifiers

PMID33099429
PMCPMC7594100
OpenAlexW3086757954

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.